Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab. (Q50764332)

From Wikidata

Jump to navigation Jump to search

scientific article published on 29 March 2017

Language	Label	Description	Also known as
English	Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab.	scientific article published on 29 March 2017

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28357697%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28357697%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

inflammatory bowel diseases

0 references

Edward L Barnes

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28357697%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

author name string

Jessica R Allegretti

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28357697%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Betsey Stevens

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28357697%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Margaret Storm

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28357697%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Ashwin Ananthakrishnan

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28357697%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Vijay Yajnik

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28357697%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Joshua Korzenik

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28357697%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

publication date

29 March 2017

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28357697%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Digestive Diseases and Sciences

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28357697%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

62

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28357697%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

1590-1596

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28357697%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28357697%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

https://scigraph.springernature.com/pub.10.1007/s10620-017-4549-3

0 references

The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5661939

10 July 2018

Integrin antagonists as potential therapeutic options for the treatment of Crohn's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5661939

10 July 2018

Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5661939

10 July 2018

Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5661939

10 July 2018

Vedolizumab for the treatment of moderately to severely active ulcerative colitis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5661939

10 July 2018

Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5661939

10 July 2018

Vedolizumab as induction and maintenance therapy for Crohn's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5661939

10 July 2018

Vedolizumab as induction and maintenance therapy for ulcerative colitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5661939

10 July 2018

The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5661939

10 July 2018

Positioning biologic agents in the treatment of Crohn's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5661939

10 July 2018

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5661939

10 July 2018

Infliximab for induction and maintenance therapy for ulcerative colitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5661939

10 July 2018

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5661939

10 July 2018

A simple clinical colitis activity index

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5661939

10 July 2018

A simple index of Crohn's-disease activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5661939

10 July 2018

Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5661939

14 August 2018

Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5661939

14 August 2018

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5661939

14 August 2018

Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects

1 reference

https://api.crossref.org/works/10.1007%2FS10620-017-4549-3

21 January 2018

The safety of vedolizumab for ulcerative colitis and Crohn's disease

1 reference

https://api.crossref.org/works/10.1007%2FS10620-017-4549-3

21 January 2018

Comparative Effectiveness of Immunosuppressants and Biologics for Inducing and Maintaining Remission in Crohn's Disease: A Network Meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS10620-017-4549-3

21 January 2018

Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population

1 reference

https://pubmed.ncbi.nlm.nih.gov/28357697

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10620-017-4549-3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28357697%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28357697%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28357697%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50764332&oldid=1459851997"